[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetic-gastroparesis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetic-gastroparesis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,68,98,131,155,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100413256","pyloric-sphincter-abnormalities-in-patients-with-gastroparesis-symptoms-100413256",false,"NCT04661215","Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms","PSAGS","Inclusion Criteria FOR SYMPTOMATIC PARTICIPANTS:\n\n1. Provision of signed and dated informed consent form.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Male or female, aged 18-85\n4. Symptoms of gastroparesis, either diabetic or idiopathic etiology\n5. Symptoms of gastroparesis with minimum Gastroparesis Cardinal Symptom Index (GCSI) score of 2.0\n6. Individual will have had a prior 4-hour gastric emptying scintigraphy test performed for clinical evaluation within the last 6 months. This gastric emptying test would be done for clinical evaluation and is not part of the research study. From these participants with gastroparesis symptoms, we will include those with delayed gastric emptying as well as those with normal gastric emptying.\n7. Participant must not initiate any new treatments until completion of the study procedures.\n8. Willingness to:\n\n   1. Stop histamine 2 antagonists, prokinetics (e.g., metoclopramide, erythromycin, domperidone, prucalopride), narcotics, anticholinergics, constipation medications (over the counter laxatives, isotonic polyethylene glycol (PEG) electrolyte preparations (e.g. MiraLax), prescription laxatives (e.g. lubiprostone), proton pump inhibitors, cannabinoids, and cannabidiol (CBD) for 3 days prior to each visit;\n   2. Abstain from food and water after midnight (at least for 8 hours) before the start of each visit until after the visit.\n\nINCLUSION CRITERIA FOR CONTROL PARTICIPANTS\n\n1. Provision of signed and dated informed consent form\n2. Male or female, aged 18 or older\n3. Undergoing an upper endoscopy for their clinical evaluation of diarrhea, GI bleed, or iron-deficiency anemia, or evaluation for bariatric surgery.\n4. Do not have upper GI symptoms greater than 1 as assessed by the Gastroparesis Cardinal Symptom Index (GCSI) of PAGI-SYM questionnaire.\n\nEXCLUSION CRITERIA:\n\n1. Prior gut lumen surgery on the esophagus or the stomach, including Nissen fundoplication.\n2. Prior surgery on the pylorus (G-POEM, surgical pyloroplasty, surgical pyloromyotomy)\n3. Known history of achalasia or esophageal stricture\n4. Known history of physiological or mechanical GI obstruction\n5. Abnormalities seen on a prior upper endoscopy placing patient at increased risk:\n\n   * Ulcer of the esophagus, stomach, or duodenum\n   * Esophageal varices\n6. Individuals at risk for prolonging the endoscopy procedure: severe chronic pulmonary disease, severe food retention in the stomach on endoscopy.\n7. Presence of significant gastric or duodenal pathology that could be expected to cause dysmotility (e.g. significant inflammation, infiltrate disorders etc)\n8. Individuals with a history of other chronic disease potentially causative of gastrointestinal symptom\n9. Acute or chronic renal insufficiency\n10. Current eating disorders\n11. Females who are pregnant. A urine pregnancy test is routinely obtained on all females immediately prior to endoscopic procedures.\n12. Individuals with contraindications for endoscopy, including bleeding abnormalities\n13. Allergy to eggs preventing sedation with propofol and\u002For gastric emptying test\n14. Significant dysphagia\n15. Prior inflammatory bowel disease, Crohn's\n16. History of any esophageal\u002Fgastric\u002Fpyloric injection of botulinum toxin\n17. Patients on daily opioid use or \\>3 day\u002Fweek use\n18. Use of glucagon-like peptide 1 (GLP1) receptor agonists or Sodium-Glucose Transport Protein 2 (SGLT2); Gastric inhibitory polypeptide (GIP)- glucagon-like peptide (GLP) combo",true,"ALL","18 Years","85 Years",{"count":21,"type":22},150,"ESTIMATED","OBSERVATIONAL","The overall objective of this study is to determine if there are pyloric sphincter abnormalities in patients with gastroparesis symptoms and determine how prevalent these abnormalities are using tests to assess the pyloric sphincter - endoluminal functional luminal imaging probe (Endoflip™), water load satiety testing (WLST), and high-resolution cutaneous electrogastrography (HR-EGG) using Gastric Alimetry™ System.",[26,27,28],"Gastroparesis","Idiopathic Gastric Motility Disorder","Diabetic Gastroparesis","RECRUITING","2026-03-30",{"date":32,"type":33},"2026-04-03","ACTUAL",{"date":35,"type":33},"2026-01-13",{"date":37,"type":22},"2027-04-15",{"name":39,"class":40},"Johns Hopkins Bloomberg School of Public Health","OTHER",5,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":52,"studyType":23,"phases":4,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100617912","correlation-between-advanced-glycation-end-products-and-gastric-motility-disorder-in-diabetes-gastroparesis-100617912","NCT07324785","Correlation Between Advanced Glycation End Products and Gastric Motility Disorder in Diabetes Gastroparesis","The Role and Mechanism of SphK1\u002FS1P\u002FFOXO1 Axis Regulating KATP Channel Mediated Gastric Smooth Muscle Dysfunction in Diabetes Gastroparesis","Inclusion Criteria for diabetes gastroparesis group:\n\n* Meet the diagnostic criteria for diabetes\n* Presence of symptoms (see assessment of Gastroparesis Cardinal Symptom Index)\n* Age range from 18 to 75 years old\n* Voluntarily participate and sign an informed consent form\n\nInclusion Criteria for control group:\n\n* No history of diabetes\n* No symptoms (see assessment of Gastroparesis Cardinal Symptom Index)\n* Age range from 18 to 75 years old\n* Voluntarily participate and sign an informed consent form\n\nExclusion Criteria for diabetes gastroparesis group and control group:\n\n* Currently taking prokinetic drugs, anticholinergic drugs, and dopamine drugs that may affect gastric motility\n* Has a history of gastrointestinal surgery\n* Pregnant or preparing to conceive\n* There are neurological disorders such as Parkinson's disease that affect gastrointestinal function\n* Outlet obstruction caused by organic lesions in the pylorus","75 Years",{"count":51,"type":22},50,"2 Weeks","This study is a prospective observational study. The study will explore the correlation between advanced glycation end products and gastric motility disorder in diabetic gastroparesis（DGP) through the collection of blood and gastric tissue samples and relevant data of patients with DGP and control group patients without diabetes history and gastroparesis symptoms.",[28],[56,57],"Diabetic gastroparesis","Advanced glycation end products","2026-02-14",{"date":60,"type":33},"2026-02-17",{"date":62,"type":33},"2026-01-07",{"date":64,"type":22},"2027-05-31",{"name":66,"class":40},"Northern Jiangsu People's Hospital",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":67},"100542234","washed-microbiota-transplantation-for-diabetic-gastroparesis-100542234","NCT06340217","Washed Microbiota Transplantation for Diabetic Gastroparesis","The Efficacy and Safety of WMT in the Treatment of Diabetic Gastroparesis: A Multicenter, Randomized, Double-blind, Placebo-controlled Study","Inclusion Criteria:\n\nSubjects must meet all of the following inclusion criteria to enter the study:\n\n1. Diagnosed with diabetes for over 1 year;\n2. Accompanied by symptoms such as abdominal bloating, early satiety, persisting for at least 3 months, with a GCSI Total Score greater than\u002Fequal to 2.3;\n3. Objective evidence of delayed gastric emptying within the past 3 months, including but not limited to scintigraphic gastric emptying or gastric ultrasound;\n4. Upper gastrointestinal obstructive lesions were ruled out by imaging or endoscopic examination within the past 3 months;\n5. Males and nonpregnant, non-breastfeeding females who are aged more than 18 years and sign the informed consent form;\n6. The subject or his\u002Fher legal representative gives informed consent, fully understands the purpose of the study, is able to communicate effectively with the investigator, and comprehends and complies with the requirements set forth in the study.\n\nExclusion Criteria:\n\nSubjects meeting any of the following exclusion criteria must be excluded from the study:\n\nSubjects who:\n\n1. Have any upper gastrointestinal pathology other than diabetic gastroparesis that would require therapy other than that provided in this trial;\n2. Have a prior history of gastric surgery, including but not limited to gastric bypass, gastrectomy, gastric banding, pyloroplasty, fundoplication, or vagotomy in past 1 year;\n3. Have any organic\u002Fneurological disease that is suspected to be causing gastroparesis, other than diabetes;\n4. Have been using medications affecting gastrointestinal motility, such as GLP-1 agonists;\n5. Have contraindications for intestinal tubing;\n6. Have a history of medication that regulate intestinal microbiome in last 48 hours;\n7. Have serious diabetic complications need immediately be dealt, such as diabetic ketoacidosis\n8. Have poor lung function and those deemed by the investigator to be affected by the study treatment, such as during COPD exacerbations;\n9. Have any of the following abnormalities in cardiac function and cardiac performance:\n\n   * Cardiac function rating≥Ⅲ according to New York Heart Association (NYHA);\n   * New myocardial infarction or unstable angina pectoris within 6 months;\n   * Electrocardiogram indicated prolonged QTc interval (male QTc≥450ms, female QTc≥470ms);\n   * requiring drug intervention (more than Ⅱ atrioventricular block).\n10. Have preexisting hepatic disease that meets Child-Pugh Class B (moderate; total score 7 to 9 points) or C (severe; total score 10 to 15 points);\n11. Kidney disease with KDIGO stage 3b (GFR\\\u003C45 ml\u002Fmin\u002F1.73m2) or above;\n12. Have infectious diseases such as active hepatitis (requiring long-term use of drugs), HIV or active tuberculosis;\n13. Have a history of drug abuse, alcoholism (defined as consuming more than 14 units per week, with 1 unit equivalent to 360 mL of beer, 45 mL of 40% alcohol, or 150 mL of wine), or substance misuse;\n14. Other significant systemic illnesses, such as malignant tumors;\n15. Have other situations in which the investigator deems it inappropriate to participate in this study.","100 Years",{"count":77,"type":22},46,"INTERVENTIONAL",[80],"NA","This is a randomized controlled trial to explore the efficacy and safety of washed microbiota transplantation (WMT) for diabetic gastroparesis (DGP) patients.",[28],[84,85,86,87,88],"washed microbiota transplantation","diabetic gastroparesis","randomized controlled trial","transendoscopic enteral tube","microbiota medicine","2025-09-03",{"date":91,"type":33},"2025-09-10",{"date":93,"type":33},"2024-04-01",{"date":95,"type":22},"2029-07",{"name":97,"class":40},"The Second Hospital of Nanjing Medical University",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":105,"enrollmentInfo":4,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":127,"locationsCount":130},"100398963","single-patient-expanded-access-protocol-for-tradipitant-in-a-single-patient-with-gastroparesis-100398963","NCT04474990","Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis","VP-VLY-686-3303: Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis","Inclusion Criteria:\n\n* Identified subject who requested expanded access\n* Diagnosed with gastroparesis\n* Demonstrated delayed gastric emptying\n* Presence of moderate to severe nausea\n* Patient does not qualify for or does not have access to other clinical trials with tradipitant;\n\nExclusion Criteria:\n\n* Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis\n* A positive test for drugs of abuse at the screening or evaluation visits;\n* Exposure to any investigational medication in the past 60 days other than tradipitant\n* Gastrectomy, fundoplication, vagotomy, pyloroplasty, bariatric surgery, or gastric stimulation device surgically implanted within the last year\n* Any other reason as determined by the Investigator which may lead to an unfavorable risk-benefit ratio to treatment;","70 Years","EXPANDED_ACCESS","Primary Objective: To treat a single patient with gastroparesis who has requested expanded access with tradipitant",[26,28],[110,111,112,113,114,115,116,117,118,119,120,121,122],"gastroparesis","idiopathic","diabetic","tradipitant","nausea","vomiting","stomach","motility","functional","NK-1 antagonist","neurokinin 1 receptor","substance p","expanded access","AVAILABLE","2025-08-18",{"date":126,"type":33},"2025-08-24",{"name":128,"class":129},"Vanda Pharmaceuticals","INDUSTRY",15,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":105,"enrollmentInfo":138,"targetDuration":4,"studyType":78,"phases":140,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100580381","phase-3-open-label-safety-study-of-tradipitant-in-idiopathic-and-diabetic-gastroparesis-100580381","NCT06836557","Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis","A Multicenter, Open Label, 3-Month Safety Study with Tradipitant in Patients with Idiopathic or Diabetic Gastroparesis","Inclusion Criteria:\n\n* Diagnosed with gastroparesis\n* Demonstrated delayed gastric emptying\n* Presence of moderate to severe nausea\n* Body Mass Index (BMI) of ≥18 and ≤40 kg\u002Fm2\n\nExclusion Criteria:\n\n* Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis\n* A positive test for drugs of abuse at the screening or evaluation visits\n* Pregnancy or nursing\n* Evidence of uncontrolled blood glucose (including HbA1C \\>11% at screening or metabolic crisis in past 60 days)",{"count":139,"type":22},100,[141],"PHASE3","This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.",[144,28,26],"Idiopathic Gastroparesis",[110,111,112,113,114,115,116,117,118,119,120,121],"2025-02-14",{"date":148,"type":33},"2025-02-20",{"date":150,"type":33},"2024-01-09",{"date":152,"type":22},"2025-12",{"name":128,"class":129},3,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":161,"targetDuration":4,"studyType":78,"phases":163,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":67},"100542281","washed-microbiota-transplantation-alleviates-diabetic-gastrointestinal-motility-disorders-an-efficacy-and-safety-study-100542281","NCT06340828","Washed Microbiota Transplantation Alleviates Diabetic Gastrointestinal Motility Disorders: an Efficacy and Safety Study","Inclusion Criteria:\n\n* Clinical diagnosis of type 2 diabetes and diabetic gastrointestinal motility disorder.\n* Glycated hemoglobin (HbA1c) \\\u003C 11.0%.\n\nExclusion Criteria:\n\n* Insulin dependent diabetes;\n* Active infections, antibiotics-using, inflammatory bowel disease, irritable bowel syndrome, or other severe gastrointestinal organic disease;\n* Severe diabetic complications;\n* Thyroid disease, malignancies, severe cognitive impairment and mental disease;\n* Alcohol or substance abuse;\n* Pregnancy or lactation.",{"count":162,"type":22},40,[80],"The goal of this clinical trial is to learn about effectiveness and safety of washing microbiota transplantation in diabetic gastrointestinal motility disorders participant population. The main questions it aims to answer are:\n\n* The risk factors of diabetic gastrointestinal motility disorders in routine clinical data or biochemical tests.\n* The composition of gut microbiota in diabetic gastrointestinal motility disorders patients and potential pathogenic bacteria.\n* The efficacy of washing microbiota transplantation in the clinical treatment of diabetic gastrointestinal motility disorders patients and potential factors that may influence treatment outcomes.\n* The potential mechanisms of washing microbiota transplantation in treating diabetic gastrointestinal motility disorders patients.\n\nParticipants will be collected fasting venous blood and random stool samples before treatment and at week 12 post-treatment, conducting scale assessments before treatment and at weeks 1, 4, and 12 post-treatment.",[28,166,167,168],"Diabetic Gastropathy","Diabetic Gastroenteropathy","Diabetic Gastroparesis Associated With Type 2 Diabetes Mellitus","NOT_YET_RECRUITING",{"date":171,"type":33},"2024-04-03",{"date":173,"type":22},"2024-04-20",{"date":175,"type":22},"2027-07-20",{"name":97,"class":40},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":184,"maxAge":105,"enrollmentInfo":185,"targetDuration":186,"studyType":23,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":4},"100484163","gastroparesis-in-type2-diabetic-patient-100484163","NCT05584462","Gastroparesis in type2 Diabetic Patient","Prevalence Of Gastroparesis In Type2 Diabetic Patients In Assiut University Hospital And Value Of Nuclear Imaging In Diagnosis","Inclusion Criteria:\n\n1. Type 2 DM\n2. Age \\\u003C 40 years\n3. \\>5 years of DM\n\nExclusion Criteria:\n\n1. Type 1 DM\n2. History of GIT surgry\n3. Medical disease affect gastric emptying\n4. Using of prokinetic","40 Years",{"count":139,"type":22},"1 Day","Gastroparesis is defined by objective delaying of gastric emptying without any evidence of mechanical obstruction. Diabetic gastroparesis is a potential complication that occurs in the setting of poorly controlled diabetes, resulting from dysfunction in the coordination and function of the autonomic nervous system, neurons, and specialized pacemaker cells (interstitial cells of Cajal, ICC) of the stomach and intestine, and the smooth muscle cells of the gastrointestinal tract",[28],"2023-01-13",{"date":191,"type":33},"2023-01-17",{"date":193,"type":22},"2023-11-01",{"date":195,"type":22},"2027-01-01",{"name":197,"class":40},"Assiut University"]